Gastroenterologists can now add tofacitinib (Xeljanz) to their list of PBS-subsidised ulcerative colitis (UC) treatments. From 1 July, the Janus kinase (JAK) inhibitor will be available on the PBS for moderate to severe ulcerative colitis (MSUC) in people who are aged 18 years or over, have failed to achieve adequate responses to conventional therapies and ...
Tofacitinib becomes first JAK inhibitor to be PBS listed for UC
By Natasha Doyle
1 Jul 2021